64.01
-0.49
(-0.76%)
May 17 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 63.30 - 65.30 |
| 52 week | 34.30 - 71.56 |
| Open | 64.58 |
| Vol / Avg. | 1.46M/1.24M |
| Mkt cap | 8.89B |
| P/E | - |
| Div/yield | - |
| EPS | -1.05 |
| Shares | 138.87M |
| Beta | 1.24 |
| Inst. own | 104% |
Events
Jul 29, 2013
Q2 2013 BioMarin Pharmaceutical Inc. Earnings Release
May 21, 2013
BioMarin Pharmaceutical Inc. at UBS Global Healthcare Conference
- 9:00AM EDT -
May 15, 2013
BioMarin Pharmaceutical Inc. Annual Shareholder Meeting
May 7, 2013
BioMarin Pharmaceutical Inc. at Robert W Baird and Co Growth Stock Conference
Apr 25, 2013
Q1 2013 BioMarin Pharmaceutical Inc. Earnings Conference Call
Apr 23, 2013
BioMarin Pharmaceutical Inc. at Biotechnology Industry Organization (BIO) International Convention
Apr 22, 2013
Q1 2013 BioMarin Pharmaceutical Inc. Earnings Release
Mar 19, 2013
BioMarin Pharmaceutical Inc. BMN-701 Phase 1/2 Trial Results Conference Call
Mar 6, 2013
BioMarin Pharmaceutical Inc. at Credit Suisse Healthcare Conference
Mar 4, 2013
BioMarin Pharmaceutical Inc. at Cowen Health Care Conference
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -31.12% | -22.84% |
| Operating margin | -33.88% | -22.01% |
| EBITD margin | - | -11.62% |
| Return on average assets | -9.98% | -7.87% |
| Return on average equity | -14.09% | -12.78% |
| Employees | 1,089 | - |
| Carbon Disclosure Rating | - | - |
Address
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
BioMarin Pharmaceutical Inc. (BioMarin) develops and commercializes pharmaceuticals for serious diseases and medical conditions. As of December 31, 2011, its product portfolio includes four approved products and multiple investigational product candidates. Approved products include Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). As of December 31, 2011, BioMarin conducted clinical trials on a number of investigational product candidates for the treatment of various diseases, including GALNS; PEG-PAL, an enzyme substitution therapy for the treatment of phenylketonuria (PKU); BMN-701, an enzyme replacement therapy; BMN-673, an orally available poly (ADP-ribose) polymerase, or PARP inhibitor for the treatment of patients with certain cancers, and BMN-111, a peptide therapeutic for the treatment of achondroplasia. In January 2013, the Company acquired Zacharon Pharmaceuticals.
Officers and directors
| Pierre Lapalme | Independent Chairman of the Board | |
| Jean-Jacques Bienaime | Chief Executive Officer, Director | |
| Daniel K. Spiegelman | Chief Financial Officer, Executive Vice President | |
| Robert A. Baffi Ph.D. | Executive Vice President - Technical Operations | |
| Henry J. Fuchs M.D., Ph.D. | Executive Vice President and Chief Medical Officer | |
| G. Eric Davis | Senior Vice President, General Counsel, Secretary | |
| Mark Wood | Senior Vice President - Human Resources & Corporate Affairs | |
| Jeff Ajer | Senior Vice President, Chief Commercial Officer | |
| Brian R. Mueller | Vice President, Chief Accounting Officer, Corporate Controller | |
| Kenneth M. Bate | Independent Director |